Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

MET is a driver oncogene in non-small-cell lung cancer (NSCLC), and its amplification is associated with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A 56-year-old Japanese male with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation received e...

Full description

Bibliographic Details
Main Authors: Katsuhiro Yoshimura, MD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Yusuke Inoue, MD, Noriyuki Enomoto, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Yutaro Nakamura, MD, PhD, Kengo Takeuchi, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Crizotinib
Erlotinib
MET amplification
Non-small-cell lung cancer
Resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007117300308

Internet

http://www.sciencedirect.com/science/article/pii/S2213007117300308

Similar Items